---
abstract: Medulloblastoma is the most common malignant brain tumor in children. Current
  treatment decisions are based on clinical variables. Novel tumor-derived biomarkers
  may improve the risk stratification of medulloblastoma patients.
authors: Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, Wittmann A,
  Devens F, Gerber NU, Joos S, Kulozik A, Reifenberger G, Rutkowski S, Wiestler OD,
  Radlwimmer B, Scheurlen W, Lichter P and Korshunov A.
contact:
  email: s.p   ster@dkfz.de
  name: Stefan Pfister
counts:
  biosamples: 101
  samples_acgh: 101
  samples_ccgh: 0
  samples_wes: 0
  samples_wgs: 0
external_identifiers:
- pubmed:19255330
- geo:GSE8634
geo_data:
  geo_json:
    coordinates:
    - 8.69
    - 49.41
    type: Point
  info:
    city: Heidelberg
    continent: Europe
    country: Germany
    label: Heidelberg, Germany, Europe
    precision: city
journal: 'J Clin Oncol 27, 10 (2009): 1627-36.'
label: 'Pfister et al. (2009): Outcome Prediction in Pediatric Medulloblastoma Based
  on DNA Copy-Number Aberrations of ...'
notes: ~
pmid: 19255330
title: Outcome Prediction in Pediatric Medulloblastoma Based on DNA Copy-Number Aberrations
  of Chromosomes 6q and 17q and the Myc and Mycn Loci.
year: 2009
